Offers of patented technologies open for licensing

SJT Molecular Research

New family of molecules with oral therapeutic potential in obesity, hepatic steatosis, NASH, hypertension, dyslipidemia and type 2 diabetes

SJT Molecuar Research is a biotechnology company recognized by a prestigious team of collaborators, CROs and universities from several continents.

Innovation on Diabetes +

Efficacy comparable to reference antidiabetics (metformin, pioglitazone)
Glucose regulatory activity by insulin sensitization
No detectable toxicity in animal models
Worldwide patent protection

Additional information

Positive cardiovascular effects by reducing systolic arterial pressure.
Significant reduction of obesity.
Proved regulating effect in diabetes, hypertension, dyslipidemia, overweight, hepatic steatosis and NASH.
Simple method of synthesis with high yield and purity.
3 compounds in pre-clinical development.


Worldwide protection of patent application PCT No. WO2012130912.

Currently we have been granted the national phases of this international patent application in:

Russia, RU2615136 (C2)
Israel, IL228630
South Korea, KR101784284 (B1)
Mexico, MX349254

In addition, the international patent request has entered the regional phase in China, Brazil, Canada and India among others.

The use of all the compounds is protected for the treatment of the metabolic syndrome in general and for specific etiologies associated with the syndrome including diabetes, hypertension, dyslipidemia, obesity, hepatic steatosis and NASH.


New polypeptides, kits and methods for the isolation of SUMOylated proteins

CIC bioGUNE is a research center exploring the interface between Chemistry and Biomedicine, with emphasis on Structural, Molecular and Cell Biology, with the aim to create new diagnostic methods and promote development of advanced therapies.

Innovation in protein isolation

High efficacy method for the isolation of post-translationally modified proteins by addition of SUMO (small ubiquitin modifier) protein by affinity binding of said proteins to the new polypeptides. New polypeptides contain tandem arrangements of SUMO interacting motifs (SIM).

Additional information

SUMO protein regulates protein activity and stability.
Several SUMOylated proteins have been described: oncogenic proteins, such as PML and transport proteins, such as RanGAP1.
The new polypeptides, kits and methods allow identification of SUMO substrates and study of SUMO-regulated processes.


International patent application PCT No. WO 2012/054039

National phases of the international application are currently granted in:
USA, US9434765 (B2)
Europe, EP2714727 (B1), validated in Germany, France, United Kingdom, Italy and Spain
All patents have been prosecuted by the firm Manuel Illescas y Asociados, S.L.U.

Polypeptides comprising SUMO interacting motifs (SIM), processes for obtaining said polypeptides, kits comprising said polypeptides, polynucleotides encoding said polypeptides, gene constructs, vectors and cells comprising said polynucleotides and methods and/or uses for the isolation of SUMOylated proteins, based on said polypeptides, are protected.


Parque Tecnológico de Bizkaia, Ibaizabal Bidea, Edificio 801
48160 Derio (BIZKAIA)
Alfonso Egaña


New recombinant mutant enzyme prethrombin-2, autocatalytically activated into active thrombin

CIC biomaGUNE is a research center at the interface between the chemical, biological and physical sciences and with a main emphasis on the study of the interaction of biofunctional nanostructures with biological systems, its applications and properties at the molecular and nanometer scale.

Innovation in hemostasis

The recombinant mutant enzyme prethrombin-2 contains a cleavage site for thrombin and is autocatalytically activated into active thrombin.
The present invention provides recombinant mutant human and murine prethrombin-2 with autocatalytic activation activity. The product resulting from the activation of this proenzyme with thrombin, catalyses the activation of the proenzyme in an autocatalytic activation process. The result is a rapidly spreading cascade of prethrombin conversion that results in an immediate effect associated to the thrombin activity.
In the absence of thrombin or other activating agent, the proenzyme is completely stable.

Additional information

Autocatalytic prethrombin-2 is highly stable.
Compatible with large-scale thrombin production using bacterial expression systems.
Example applications include its use as hemostatic drug; thrombin detection; prothrombin detection in human plasma and its use as biochemical assays by signal amplification cascade.


International patent application PCT No. WO 2013/064542

National phases of the international application are currently granted in:
USA, US9334526 (B2)
Europe, EP2773756 (B1), validated in Germany, France, United Kingdom, Italy and Spain
National phase in Canada is pending to be granted.
All patents have been prosecuted by the firm Manuel Illescas y Asociados, S.L.U.

Recombinant mutant enzyme prethrombin-2, uses and kits for detecting thrombin/prothrombin and methods for producing thrombin are protected.


Parque Tecnológico de San Sebastián
Pº Miramón, Ed. Empresarial C
20009 San Sebastián (GIPUZKOA)
Alfonso Egaña
Marcos Simón

Dr. Uriol Rivera

Dr. Uriol Rivera, nephrologist, is an expert in inflammatory anemia, inflammatory processes and kidney diseases.

Paricalcitol for the treatment of inflammatory anaemia

Inflammatory anemia is a frequent pathology without specific treatment.
The treatment of inflammatory anemia with paricalcitol, a selective activator of vitamin D receptor, increases plasma erythropoietin levels in patients and allows the reduction of the amount of iron and erythropoiesis-stimulating agents that are administered to these patients.

Additional information

Paricalcitol can be administered in combination with erythropoiesis-stimulating agents: epoetin alfa, epoetin beta, epoetin delta, epoetin zeta, darbepoetin alfa and CERA.
Inflammatory anaemia is a frequent inflammatory complication in several chronic pathologies: heart failure, neoplasms, respiratory diseases and chronic kidney disease (CKD), among others and also occurs in cancer or aging.


International patent application PCT No. WO 2015/121022.

The patent is currently granted in:
Spain, ES2472040 (B1)
The patent is pending to be granted in the following countries: Europe, Russia, USA, China, Japan, South Korea, Canada, Mexico, Australia, Israel, Uruguay, Venezuela, Jamaica and Kuwait
All patents are being prosecuted by the firm Manuel Illescas y Asociados, S.L.U.

Protection for pharmaceutical compositions comprising paricalcitol in combination with erythropoiesis-stimulating agents and its use in treating inflammatory anaemia according to a regimen of daily or weekly administration of paricalcitol.

Dr. Uriol Rivera

Dr. Uriol Rivera